Track the PolyPeptide Group AG stock price and the full insider trade history of the company, a publicly traded company based in Switzerland. Shares are quoted on the CH market, under the oversight of SIX SER. Operating in the Health Care sector, PolyPeptide Group AG has published 10 public disclosures. Market capitalisation: €1.5bn. The latest transaction was disclosed on 9 April 2025 (Purchase). The full history is accessible without an account.
10
Insider Decl.
n/a
Thresholds
€4m
10 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate PolyPeptide Group AG Buy (bullish), based on 6 analysts. Average price target: CHF 38.81.
28Σ signal
Buys €4mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,653 of 29,024 companies
19.9
score / 100
Value
20
Quality
20
FCF yld-2.2%
Earn yld-1.5%
EV/EBITDA55.8x
ROE-6.1%
Gross mgn17%
Net mgn-5.4%
Debt/EBITDA4.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 April 2025
Declarations10 total
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directors·Executives·
22,041 shares@ CHF 16.84150.045% mcap11.2% of flowISINISIN CH1110760852SIX:T1NAA00062
10 of 10 declarations
About PolyPeptide Group AG
PolyPeptide Group AG is a company specializing in the development and manufacturing of peptides for the pharmaceutical and biopharmaceutical sectors. It is listed on the Swiss Exchange (XSWX).